Speaker:

Megan May, PharmD, BCOP

Ambulatory Oncology Clinical Pharmacy Specialist

Baptist Health System

Lexington, Kentucky

Megan May, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

At the completion of this activity, pharmacists, physicians, and nurses will be able to:

• Compare data that support approved and emerging therapy options in adjuvant and metastatic melanoma
• Employ best practices of a multidisciplinary team to address adverse effects and treatment adherence in patients with melanoma

At the completion of this activity, pharmacy technicians will be able to:

• Discuss data that support approved and emerging therapy options in adjuvant and metastatic melanoma
• Give examples of best practices to address adverse effects and treatment adherence in patients with melanoma

Activity Overview

Use of immune checkpoint inhibitors and targeted BRAF/MEK combination therapy have expanded treatment options and improved outcomes for patients with adjuvant and metastatic melanoma. Members of the oncology health care team must be familiar with biomarkers to guide treatment selection and therapy sequencing, as these emerging and investigational regimens have the potential to increase recurrence-free survival rates in patients with melanoma. However, with multiple agents and routes of administration used in a single regimen, treatment for adjuvant and metastatic melanoma can be complex. Monitoring for therapy tolerance and specific adverse effects of melanoma treatment regimens requires coordination of care among the multidisciplinary oncology care team. Considerations for effective patient counseling and management throughout the continuum of treatment will be discussed.